Taysha Gene Therapies Inc Ordinary Shares TSHA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TSHA is a good fit for your portfolio.
News
-
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Thinking about buying stock in Archer Aviation, Lantern Pharma, Taysha Gene Therapies, Pagaya Technologies, or Blink Charging?
-
Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates
-
Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19
-
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Taysha Gene Therapies Announces Updates to TSHA-102 Clinical Program in Rett Syndrome
-
Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs
-
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Trading Information
- Previous Close Price
- $2.43
- Day Range
- $2.35–2.51
- 52-Week Range
- $0.50–3.89
- Bid/Ask
- $2.44 / $2.60
- Market Cap
- $452.58 Mil
- Volume/Avg
- 1.4 Mil / 2.8 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 18.19
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 52
- Website
- https://www.tayshagtx.com
Valuation
|
Metric
|
TSHA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 6.04 |
Price/Sales | 18.19 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
TSHA
|
|---|---|
Quick Ratio | 3.92 |
Current Ratio | 4.08 |
Interest Coverage | −22.04 |
Quick Ratio
TSHA
Profitability
|
Metric
|
TSHA
|
|---|---|
Return on Assets (Normalized) | −48.39% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −117.00% |
Return on Assets
TSHA
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Vxfrkqvjs | Gssc | $572.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Qjcyffhq | Vqjdmr | $103.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Fkvtdwq | Ykpttn | $99.6 Bil | |
MRNA
| Moderna Inc | Rqtqflsjw | Lpydt | $42.7 Bil | |
ARGX
| argenx SE ADR | Ykfhckl | Kgln | $22.2 Bil | |
BNTX
| BioNTech SE ADR | Gynjvrwl | Vkqt | $21.7 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Wjxzyjkkw | Fkpfvb | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ghrlsbnpq | Gjjyv | $15.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Tnrqnmtgj | Jdzql | $12.7 Bil | |
INCY
| Incyte Corp | Cgdfgnwyx | Zsyvqtd | $11.9 Bil |